



**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
08 - 10 October 2019
Executive Board Room, Geneva, Switzerland**

Agenda

Tuesday, 08 October 2019

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Welcome – introduction of participants A. CRAVIOTO. Chair of SAGE.		20 min.
10:20	Report from Director, IVB and Regional Updates - Session 1 Global report including key updates and challenges from regions. K. O'BRIEN. WHO. 30 min.	FOR INFORMATION	1h 30 min.
10:50	Coffee/Tea break	Break	30 min.
11:20	Cont. Session 1 Key updates and challenges from regions. Regional Advisers. WHO. 15 min. Discussion: 45 min.	FOR INFORMATION	
12:20	Report from Gavi, the Vaccine Alliance - Session 2 Report from Gavi, the Vaccine Alliance. S. BERKLEY. Gavi, the Vaccine Alliance. 15 min. Discussion: 25 min.	FOR INFORMATION	40 min.
13:00	Lunch	Break	1h

14:00	Immunization Partners - Session 3 Report from the Vaccine Innovation Prioritisation Strategy (VIPS). M. MENOZZI-ARNAUD. Gavi, the Vaccine Alliance. 15 min. Discussion: 15 min.	FOR INFORMATION	30 min.
14:30	Measles and Rubella - Session 4 Session introduction. N. TURNER. Chair of SAGE Measles and Rubella Vaccines Working Group. 5 min. Rubella and CRS Control and Elimination Rubella vaccine policy update. S. DESAI. WHO. 10 min. Discussion: 10 min. Recommendations. N. TURNER. Chair of SAGE Measles and Rubella Vaccines Working Group. 5 min. Discussion: 10 min. Global update on measles and rubella, including on outbreaks K. KRETSINGER. WHO. 10 min. Discussion: 20 min.	FOR INFORMATION, DISCUSSION AND DECISION FOR DECISION <ul style="list-style-type: none"> Presentation of programmatic evidence to support policy amendments to recommendations for rubella and CRS control and elimination <p>SAGE is requested to consider the following question:</p> <ul style="list-style-type: none"> Can the recommendation to only target vaccination of women of reproductive age as part of a CRS prevention/rubella control strategy be removed? FOR INFORMATION <ul style="list-style-type: none"> Global and regional update 	3h
15:40	Coffee/tea break	Break	30 min.
16:10	Cont. Session 4 Measles and Rubella Elimination Modelling the epidemiologic impact and cost-effectiveness of different MR programme performance scenarios. M. FERRARI. Penn State University and M. Jit. Member of Measles and Rubella Working Group. 20 min. Questions and answers: 20 min. Feasibility of MR eradication. B. MOSS. JHSPH. 15 min. Questions and answers: 10 min. Recommendations. N. TURNER. Chair of SAGE Measles and Rubella Vaccines Working Group. 5 min. Discussion: 40 min.	FOR DISCUSSION AND DECISION <ul style="list-style-type: none"> Presentation of modelling and economic analysis of measles and rubella elimination Presentation of the proposed response to the World Health Assembly request to report on the feasibility and financial resource requirements for measles and rubella eradication SAGE is requested to consider the assessment of the feasibility of measles and rubella eradication for endorsement.	
18:00	End of Day		
18:15	Cocktail		

Wednesday, 09 October 2019

9:30	Human papillomavirus (HPV) Vaccine - Session 5 Session introduction and key questions. R. AGGARWAL. Chair of SAGE HPV Vaccines Working Group. 5 min. Update on access to HPV vaccine. P. BLOEM. WHO. 10 min. Systematic review of evidence on different HPV immunization strategies. N. HENSCHKE. Cochrane Response. 15 min. Ongoing trials on single-dose HPV vaccine schedule. A. KREIMER. National Cancer Institute. 10 min. Global analysis of HPV vaccine supply and demand. T. CERNUSHI. WHO. 10 min. Impact of different HPV immunization strategies in the context of supply constraint. M. BRISSON. Laval University. 15 min. Conclusions and proposed recommendations by SAGE Working Group. R. AGGARWAL. Chair of SAGE HPV Vaccines Working Group. 15 min. Discussion: 1h 10 min	FOR DISCUSSION AND DECISION Present SAGE with updated evidence on HPV vaccination schedule and barriers, and modelling of impact of HPV immunization schedules and strategies in the context of supply constraint. SAGE is requested to consider the following questions: 1. What does current evidence show on the immunogenicity and efficacy of a single dose of HPV vaccine and different intervals between the first and second doses of HPV vaccine? And what are the risks of bias of these studies? 2. What are the potential demand scenarios and the supply of HPV vaccines (short and mid-term outlook) and what could the enhanced HPV vaccine supply allocation be? 3. In light of the above conclusions and evidence, how should HPV vaccination be prioritized with respect to impact and feasibility? Overall question to SAGE: In light of the current HPV vaccine supply and the above analyses, how should HPV vaccination be prioritized with respect to impact, feasibility, and equity?	2h 30 min.
11:00	Coffee/tea break	Break	30 min.
11:30	Cont. Session 5		
12:30	Post-2020 Global Immunization Strategy/ Global Vaccine Action Plan (GVAP) - Session 6 Presentation of draft GVAP review and lessons learned report, including recommendations. N. MACDONALD. Chair of SAGE Decade of Vaccines Working Group. 20 min. Discussion: 40 min.	FOR DISCUSSION AND DECISION SAGE is asked to consider the GVAP review and recommendations for endorsement. <i>Note: The GVAP review and lessons learned report replaces the annual GVAP assessment report. It encompasses an analysis of the 2018 data.</i>	3h
13:30	Lunch	Break	1h
14:30	Cont. Session 6 Presentation of the draft post-2020 global immunization strategy ("Immunization Agenda 2030")	SAGE is asked to consider the draft Immunization Agenda 2030 for endorsement.	

08 October 2019

	K. O'BRIEN. WHO. 45 min.		
	Discussion: 1h 15 min.		
16:30	Coffee/tea break	Break	30 min.
17:00	Ebola vaccines - Session 7	FOR INFORMATION AND DISCUSSION	1h 30 min.
	Overview of SAGE recommendations and introduction to the session. F. WERE. Co-Chair of SAGE Working Group on Ebola Vaccines. 10 min.	Update on implementation of the interim Ebola vaccine recommendations and the ongoing response to the DRC outbreak.	
	Update on outbreak epidemiology. B. ARCHER. WHO. 10 min.		
	Status of implementation of SAGE interim recommendations. A. DIALLO. WHO. 10 min.		
	Preliminary observations regarding effect of rVSV ZEBOV vaccination in the Democratic Republic of the Congo (DRC). A.-M. HENAO RESTREPO. WHO. 10 min.		
	Update on status of Ebola candidate vaccines and ongoing efforts towards global vaccine security. A. COSTA. WHO. 10 min.		
	Conclusions and next steps. H. REES. Co-Chair of SAGE Working Group on Ebola Vaccines. 10 min.		
	Discussion: 30 min.		
18:30	End of day		

Thursday, 10 October 2019

09:30	Quality and Use of Immunization and Surveillance Data - Session 8	FOR DISCUSSION AND DECISION	1h 30 min.
	SAGE Immunization Data WG summary. H. SCOBIE. Members of SAGE Working Group on Quality and Use of Immunization and Surveillance Data. 15 min.	Following the April 2019 SAGE meeting, actionable recommendations were developed.	
	India: Utilization of Immunization Data to Improve Evidence-based Decision-Making. D. AHMED. WHO. 10 min	SAGE is asked to consider the draft recommendations for endorsement.	
	Western Pacific Region: data in the Regional Strategic Framework for Vaccine-preventable Diseases and Immunization 2021-2030. D.A.C. AMARASINGHE. WHO. 15 min.		
	SAGE Immunization Data WG proposed recommendations. J. JAWAD. Chair of SAGE Working Group on Quality and Use of Immunization and Surveillance Data. 5 min.		

Discussion: 45 min.			
10:30	Coffee/tea break	Break	30 min.
11:00	Cont. Session 8		
11:30	Polio – Session 9	FOR DISCUSSION AND DECISION	2h
	<p>Update from the Global Polio Eradication Initiative R. SUTTER. WHO. 30 min.</p> <p>Presentation of clinical data from novel type 2 oral polio vaccine (nOPV2) trials and plan for Emergency Use Listing (EUL). A. BANDYOPADHYAY. BMGF. 20 min.</p> <p>Report from SAGE Polio Working Group including presentation of results from “One-drop monovalent type 2 oral polio vaccine (mOPV2) study”; and call for acceleration of assessment of nOPV2 under EUL. I. JANI. Co-Chair of SAGE Polio Working Group. 30 min.</p> <p>Discussion: 40 min.</p>	<p>Update on the current status of the polio eradication program, including circulating vaccine-derived poliovirus (cVDPV) outbreaks, and on proposed revised strategies to respond to cVDPV2 outbreaks.</p> <p>SAGE is asked to discuss and consider endorsement of recommendations on:</p> <ul style="list-style-type: none"> • Acceleration of the clinical development of nOPV2 • Use of one-drop mOPV2 vaccination 	
13:30	Closing		20 min.
13:50	End of meeting		